PRESS RELEASES Guest User 2023-08-11 Guest User 2023-08-11 BiondVax Reports Second Quarter Financial Results and Provides Business Update Read More Guest User 2023-08-01 Guest User 2023-08-01 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Read More Guest User 2023-06-05 Guest User 2023-06-05 BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Read More Guest User 2023-05-15 Guest User 2023-05-15 BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update Read More Guest User 2023-04-17 Guest User 2023-04-17 BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update Read More Guest User 2023-03-16 Guest User 2023-03-16 BiondVax to Present at BIO-Europe Spring Read More Guest User 2023-02-02 Guest User 2023-02-02 BiondVax Presenting at BIO CEO & Investor Conference Read More Guest User 2023-01-23 Guest User 2023-01-23 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study Read More Guest User 2023-01-06 Guest User 2023-01-06 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Read More Guest User 2023-01-05 Guest User 2023-01-05 BiondVax to Present at Biotech Showcase 2023 Read More Newer Posts
Guest User 2023-08-11 Guest User 2023-08-11 BiondVax Reports Second Quarter Financial Results and Provides Business Update Read More
Guest User 2023-08-01 Guest User 2023-08-01 Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules Read More
Guest User 2023-06-05 Guest User 2023-06-05 BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis Read More
Guest User 2023-05-15 Guest User 2023-05-15 BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update Read More
Guest User 2023-04-17 Guest User 2023-04-17 BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update Read More
Guest User 2023-02-02 Guest User 2023-02-02 BiondVax Presenting at BIO CEO & Investor Conference Read More
Guest User 2023-01-23 Guest User 2023-01-23 BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study Read More
Guest User 2023-01-06 Guest User 2023-01-06 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study Read More
